Abstract
Photodynamic and sonodynamic therapy (PDT, SDT) are modern, non-invasive treatments applicable to different types of cancer. PHOTOGLIOBLASTER aims to develop innovative, minimally invasive strategies for the efficient and selective delivery of photo- or sono-activable sensitizers to tumor cells using recombinant viral vectors for the treatment of Glioblastoma (GBM), using two approaches. The first strategy will arm a neuro-attenuated oHSV-1 with the protein KillerRed (KR) under the control of a tumor specific promoter, to clear those oHSV-1 infected cells that have escaped from viral killing with PDT. The second strategy is based on the M13 phage, engineered to target cells expressing the glioma-specific variant of the EGFR receptor and rigged with hundreds of sensitizer molecules, excitable with deep penetrating infrared light or ultrasound. Successful results are expected to pave the road for innovative PDT/SDT cancer therapeutics with broad translational potential.
Dettagli del progetto
Responsabile scientifico: Alberto Danielli
Strutture Unibo coinvolte:
Dipartimento di Farmacia e Biotecnologie
Coordinatore:
Università degli Studi di PADOVA(Italy)
Contributo totale Unibo: Euro (EUR) 54.223,00
Durata del progetto in mesi: 24
Data di inizio
12/10/2023
Data di fine:
28/02/2026
